Abstract
The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1327-1333 |
| Number of pages | 7 |
| Journal | Clinical Infectious Diseases |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 1997 |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
Antimicrobial therapy for chronic osteomyelitis in adults : Role of the quinolones. / Rissing, John Peter.
In: Clinical Infectious Diseases, Vol. 25, No. 6, 01.01.1997, p. 1327-1333.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Antimicrobial therapy for chronic osteomyelitis in adults
T2 - Role of the quinolones
AU - Rissing, John Peter
PY - 1997/1/1
Y1 - 1997/1/1
N2 - The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.
AB - The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.
UR - http://www.scopus.com/inward/record.url?scp=0031436961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031436961&partnerID=8YFLogxK
U2 - 10.1086/516150
DO - 10.1086/516150
M3 - Review article
C2 - 9431371
AN - SCOPUS:0031436961
VL - 25
SP - 1327
EP - 1333
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 6
ER -